Hot Topics in Diabetes: the future of antidiabetics in Australia

Report Summary
The diagnosed diabetic population in Australia is growing, and patients are continuing to struggle to reach and maintain target blood glucose levels. These market drivers, combined with a preponderance of safety concerns over currently marketed antidiabetics in recent years, means that the opportunity for new and improved pipeline candidates is lucrative.

Browse all: Healthcare Market Research Reports

Features and benefits
• Provides insight into the key drivers and resistors to antidiabetic medicine uptake in Australia
• Analyzes the current diabetes treatment paradigm in Australia
• Assesses key brands in the insulin and non-insulin antidiabetics market in Australia
• Summarizes key pipeline candidates expected to launch in Australia, and their likely impacts

Highlights
Despite strong market drivers, the Australian antidiabetics market can be difficult to penetrate, with a number of leading global brands facing restrictions in approved indications and difficulties obtaining reimbursement.
With limited pipeline development in the insulin class, the major impact on growth will come from the biosimilar threat, expected to take effect in Australia from 2015. Meanwhile, glucagon-like peptide-1 will pick up market share if reimbursement difficulties can be resolved and as longer-acting molecules reach the Australian market.
Oral antidiabetics will continue to prosper, driven by a number of late-stage pipeline candidates, including a new class of sodium-dependent glucose transporter-2 inhibitors. However, the thiazolidinedione class is expected to lose market share to other oral antidiabetics with better long-term safety profiles.

OVERVIEW OF DIABETES IN AUSTRALIA
Australia-specific diabetes epidemiology
Type 1 diabetes is increasing in incidence, but overall prevalence remains low
Type 2 diabetes is highly prevalent in Australia
Australian diabetes market drivers
The prevalence of diabetes is increasing in Australia
Half of all Australian diabetes patients do not reach HbA1c target of <7%
The Australian government has committed significant funds to diabetes research and management
Launch of novel compounds will stimulate the non-insulin market
Australian diabetes market resistors
Novel antibiotic may struggle to gain Pharmaceutical Benefits Scheme listings
Biosimilars will begin to impact insulin sales
Issues with safety and efficacy of thiazolidinediones have jaded some prescribers
Health reforms aim to decrease the diabetes incidence and spending by increasing preventative care and chronic disease management programs
Strategies to access the Australian antidiabetics market
Novo Nordisk identifies itself as a diabetes-focused company and offers support services
Eli Lilly needs to improve its dissemination of physician and patient education
Merck’s campaign promoting Januvia to GPs ensured rapid product uptake

Related Reports:

Autistic Disorder Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Psoriasis Therapeutics - Pipeline Assessment and Market Forecasts to 2018